212
Participants
Start Date
March 1, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2028
PD-1 blocking antibody
Toripalimab 240mg, D1, every 3 weeks per cycle
GP
Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
IMRT
IMRT 60-66Gy, 1.8-2.0Gy/f/day
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Peking University Third Hospital, Beijing
NOT_YET_RECRUITING
Sichuan Cancer Hospital, Chengdu
NOT_YET_RECRUITING
Fujian Province Cancer Hospital, Fuzhou
RECRUITING
Guizhou Cancer Hospital, Guiyang
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
Jiangxi Cancer Hospital, Nanchang
RECRUITING
The First Affiliated Hospital of Guangxi Medical University, Nanning
NOT_YET_RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
RECRUITING
Xijing Hospital, Xi'an
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
Sun Yat-sen University
OTHER